Aptose Biosciences Inc (APTO)

Canaccord cuts Aptose Biosciences shares target, expects lead drug approval delay - Investing.com Canada

Investing.com Canada

Closing Bell: Aptose Biosciences Inc down on Wednesday (APS) - The Globe and Mail

The Globe and Mail

Aptose Biosciences Inc. (NASDAQ:APTO) Q1 2024 Earnings Call Transcript - Insider Monkey

Insider Monkey

Aptose Biosciences (NASDAQ:APTO) Rating Lowered to Sell at StockNews.com - Defense World

Defense World

Closing Bell: Aptose Biosciences Inc up on Tuesday (APS) - The Globe and Mail

The Globe and Mail

Aptose Reports Results for the First Quarter 2024 - GlobeNewswire

GlobeNewswire

Aptose Reports Results for the First Quarter 2024 - Yahoo Finance

Yahoo Finance

Why Jamf (JAMF) Stock Is Falling Today - The Globe and Mail

The Globe and Mail

Aptose Biosciences: Q1 Earnings Snapshot - Houston Chronicle

Houston Chronicle

Aptose Biosciences Inc. (NASDAQ:APTO) Given Consensus Rating of “Buy” by Analysts - Defense World

Defense World

Aptose Biosciences (APTO) Set to Announce Earnings on Tuesday - Defense World

Defense World

Aptose Biosciences (APTO) Stock Forecast and Price Target 2024 - MarketBeat

MarketBeat

Closing Bell: Aptose Biosciences Inc down on Friday (APS) - The Globe and Mail

The Globe and Mail

Closing Bell: Aptose Biosciences Inc down on Thursday (APS) - The Globe and Mail

The Globe and Mail

Closing Bell: Aptose Biosciences Inc up on Wednesday (APS) - The Globe and Mail

The Globe and Mail

Closing Bell: Aptose Biosciences Inc up on Tuesday (APS) - The Globe and Mail

The Globe and Mail

Aptose Biosciences Unveils Q1 Results and Clinical Update - TipRanks.com - TipRanks

TipRanks

Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024

GlobeNewswire Inc.

Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024 - Yahoo Finance

Yahoo Finance

Aptose Biosciences Enhances Executive Compensation and Roles - TipRanks.com - TipRanks

TipRanks

What Makes Aptose Biosciences (APTO) a New Buy Stock

Zacks Investment Research

What Makes Aptose Biosciences (APTO) a New Buy Stock - Yahoo Finance

Yahoo Finance

Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call Transcript - Yahoo Finance

Yahoo Finance

Aptose Reports Results for the Fourth Quarter and Full Year 2023

GlobeNewswire Inc.

Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024

GlobeNewswire Inc.

Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday ... - GlobeNewswire

GlobeNewswire

Assertio (ASRT) Stock Plunges 65% in 3 Months: Here's Why

Zacks Investment Research

Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option

GlobeNewswire Inc.

Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi ... - GlobeNewswire

GlobeNewswire

Thinking about buying stock in Cipher Mining, SoundHound AI, Cellectar Biosciences, Bitdeer Technologies, or Aptose ... - Marketscreener.com

Marketscreener.com

Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical

GlobeNewswire Inc.

Why Tellurian Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket

Benzinga

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday - InvestorPlace

InvestorPlace

Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting

GlobeNewswire Inc.

Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting - GlobeNewswire

GlobeNewswire

Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role

GlobeNewswire Inc.

Aptose Reports Results for the Third Quarter 2023 - Yahoo Finance

Yahoo Finance

Hanmi Pharmaceutical Invests in Aptose Biosciences - BusinessKorea

BusinessKorea

Aptose Biosciences Provides Update on Reverse Stock Split - Yahoo Finance

Yahoo Finance

3 Stocks With 1000% Upside Potential - InvestorPlace

InvestorPlace

Aptose Biosciences Inc.'s (TSE:APS) Path To Profitability - Yahoo Finance

Yahoo Finance

BioSpace Movers & Shakers: Evommune, Maravai, Aptose & More - BioSpace

BioSpace

Aptose to Present at Canaccord Genuity's 2022 Horizons in - GlobeNewswire

GlobeNewswire

Aptose Biosciences: An Assessment (NASDAQ:APTO) - Seeking Alpha

Seeking Alpha

Why Aptose Biosciences Stock Sank Today - The Motley Fool

The Motley Fool

5 'Strong Buy' Biotech Stocks to Buy for 2020 - Kiplinger's Personal Finance

Kiplinger's Personal Finance

Aptose Biosciences gains after FDA greenlights Phase 1 trial for blood cancer drug CG-806 - Proactive Investors USA

Proactive Investors USA

Aptose Biosciences (APTO) Stock Forecast and Price Target 2024 - MarketBeat

MarketBeat

Aptose Biosciences (APTO) Stock Price, News & Analysis - MarketBeat

MarketBeat